Private company

ENZO BIOCHEM INC

American biological products company based in Farmingdale2

In its 2024 annual report the company says: “We conduct our research and other product development efforts through internal research and collaborative relationships.”6

Last updated Oct 20, 2026.

Overview

$31.9MRevenue, fiscal 20243
-$26.1MNet income, fiscal 20243
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersNew York, United States2
  • Incorporated inNY4
  • Business address60 Executive Blvd, Farmingdale, Ny 117354
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI5299001N23WBO4XQ2P602
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Elzar Rabbani PH.D., 527 Madison Avenue, 10022 New York, United States2
  • Registered withCorporation and Business Entity Database (Division of Corporations, State Records and UCC, Department of State), 4074402

See how the biggest companies compare on our leaderboards

We conduct our research and other product development efforts through internal research and collaborative relationships.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-38.8%Operating margin3
-81.7%Net margin3
2.7%Revenue growth, 20243
-46.5%Return on equity3
0.00×Debt to equity3

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue41¢$17.3M
  • Research and development6¢$2.6M
  • Selling, general and admin52¢$21.7M

Out of $31.9M in revenue.3 The company lost money this year.

Financial statements

Revenue78910113$31.9M in 2024−70% since 2017
0$50.0M$100.0M$150.0M2017: $105.1M$105.1M20172018: $101.0M$101.0M2018−4%2019: $81.2M$81.2M2019−20%2020: $76.0M$76.0M2020−6%2021: $117.7M$117.7M2021+55%2022: $32.6M$32.6M2022−72%2023: $31.1M$31.1M2023−5%2024: $31.9M$31.9M2024+3%
Operating income78910113-$12.4M in 2024+293% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M0$10.0M2017: -$3.1M-$3.1M20172018: -$12.2M-$12.2M2018+286%2019: $1.7M$1.7M20192020: -$30.4M-$30.4M20202021: $692.0K$692.0K20212022: -$17.0M-$17.0M20222023: -$24.7M-$24.7M2023+45%2024: -$12.4M-$12.4M2024−50%
Net income78910113-$26.1M in 2024+941% since 2017
-$40.0M-$20.0M0$20.0M$40.0M2017: -$2.5M-$2.5M20172018: -$10.3M-$10.3M2018+312%2019: $2.5M$2.5M20192020: -$28.5M-$28.5M20202021: $7.9M$7.9M20212022: -$18.3M-$18.3M20222023: $20.3M$20.3M20232024: -$26.1M-$26.1M2024
Fiscal year20172018201920202021202220232024
Revenue$105.1M7$101.0M8$81.2M9$76.0M10$117.7M10$32.6M11$31.1M3$31.9M3
Cost of revenue$59.5M7$60.4M8$57.9M9$52.3M10$64.2M10$19.2M11$17.9M3$17.3M3
Research and development$2.9M7$3.2M8$3.2M9$4.4M10$3.3M10$2.4M11$3.9M3$2.6M3
Selling, general and admin$44.1M7$44.5M8$44.3M9$43.0M10$44.9M10$23.1M11$27.2M3$21.7M3
Operating income-$3.1M7-$12.2M8$1.7M9-$30.4M10$692.0K10-$17.0M11-$24.7M3-$12.4M3
Interest-$178.0K11$1.1M11
Income before tax-$20.3M11-$25.0M3-$9.8M3
Income tax$82.0K15-$1.1M8
Net income-$2.5M7-$10.3M8$2.5M9-$28.5M10$7.9M10-$18.3M11$20.3M3-$26.1M3
Earnings per share-$0.057-$0.228$0.059-$0.6010$0.1610-$0.3811$0.413-$0.513
Earnings per share (diluted)-$0.057-$0.228$0.059-$0.6010$0.1610-$0.3811$0.413-$0.513
Shares (weighted, basic)48.6K shares1149.2K shares350.9K shares3
Shares (weighted, diluted)48.6K shares1149.2K shares350.9K shares3

Compare ENZO BIOCHEM INC with another company

Corporate structure

ENZO BIOCHEM INC sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ENZO BIOCHEM INC

  • Beryl Capital Management LLC Filed SCHEDULE 13G/A on ENZO BIOCHEM INC, latest Nov 14, 2025 (2 filings since Jul 1, 2025)
  • Radoff Bradley Louis Filed SCHEDULE 13D/A on ENZO BIOCHEM INC, latest Aug 22, 2025 (7 filings since Oct 6, 2021)
  • Battery Ventures XIV, L.P. Filed SCHEDULE 13D on ENZO BIOCHEM INC, latest Jun 30, 2025
  • Harbert Discovery Fund, LP Filed SCHEDULE 13D/A on ENZO BIOCHEM INC, latest Jun 25, 2025 (2 filings since Oct 28, 2021)
  • 1 MAIN CAPITAL MANAGEMENT, LLC Filed SC 13G/A on ENZO BIOCHEM INC, latest Feb 14, 2024 (2 filings since Sep 11, 2023)
  • RENAISSANCE TECHNOLOGIES LLC Filed SC 13G/A on ENZO BIOCHEM INC, latest Feb 13, 2024 (3 filings since Feb 14, 2022)
  • Wolf James G. Filed SC 13D/A on ENZO BIOCHEM INC, latest Jan 23, 2023 (5 filings since Oct 1, 2021)
  • Roumell Asset Management, LLC Filed SC 13D/A on ENZO BIOCHEM INC, latest Mar 25, 2022
  • VANGUARD GROUP INC Filed SC 13G/A on ENZO BIOCHEM INC, latest Feb 10, 2022
  • Evermore Global Advisors, LLC Filed SC 13G/A on ENZO BIOCHEM INC, latest Jan 18, 2022
  • ENZO BIOCHEM INC New York, New York, United States
    • Enzo Life Sciences (ELS) AG, in Lausen, Subsidiary · Switzerland

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ENZO BIOCHEM INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land and buildings$2.1M3 Jul 31, 2024$2.1M3 Jul 31, 20230%
Buildings and improvements$11.7M3 Jul 31, 2024$12.5M3 Jul 31, 2023−6.4%
Machinery and equipment$7.1M3 Jul 31, 2024$7.0M3 Jul 31, 2023+2.3%
Leasehold improvements$1.0M3 Jul 31, 2024$887.0K3 Jul 31, 2023+17.2%
Property and equipment, before depreciation$27.1M3 Jul 31, 2024$28.3M3 Jul 31, 2023−4.3%
Accumulated depreciation$16.8M3 Jul 31, 2024$17.3M3 Jul 31, 2023−2.8%
Property and equipment, net$12.4M3 Jul 31, 2024$13.1M3 Jul 31, 2023−5.5%
Operating-lease assets (leased space)$2.8M3 Jul 31, 2024$3.6M3 Jul 31, 2023−21.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$52.4M3 Jul 31, 2024$82.4M3 Jul 31, 2023−36.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$6.8M3 Jul 31, 2024$7.9M3 Jul 31, 2023−13.9%
Raw materials$1.8M3 Jul 31, 2024$2.2M3 Jul 31, 2023−18.7%
Work in process$2.5M3 Jul 31, 2024$2.6M3 Jul 31, 2023−5.3%
Finished goods$2.6M3 Jul 31, 2024$3.1M3 Jul 31, 2023−17.8%

Properties, in its own words

The following are the principal facilities of the Company as of July 31, 2024:

Leased or · Square

The rest of Item 2

Location · Primary use · Segments · Owned · footage

Farmingdale, NY · Manufacturing, research, sales and administrative office · Products · Owned · 22,000

Farmingdale, NY · Manufacturing and administrative office · Products · Owned · 36,000

New York, NY (Note 1) · Administrative office · Corporate and Other · Leased · 11,300

Lausen, Switzerland (Note 2) · Operational headquarters in Europe, including sales and distribution · Products · Leased · 9,626

Note 1 · In June 2017, the lease was extended through June 2028. In July 2022, we sublet 7,200 square feet of this space for the remaining term of the lease, expiring June 2028.

Note 2 · In June 2019, the lease was amended and extended through July 2020 and automatically renews for one year on each anniversary.

We believe the above facilities are suitable and adequate for the Company’s current operating needs for its Products and “Corporate and Other” segments and that the production capacity in various locations is sufficient to manage services and product requirements.

We also are in a related party lease for a building formerly used by the clinical laboratory, which expires March 31, 2027.

Item 2 of the 10-K filed Oct 29, 2024.6

Leadership

Who has led ENZO BIOCHEM INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Elazar Rabbani2007–2020
  2. Hamid Erfanian2021–2022
  3. Kara Cannon2024–now

Chair

  1. Elazar Rabbani2007–2009

President

  1. Barry W. Weiner2007–2021
  2. Carl W. Balezentis2007–2008
  3. Christine Fischette2008
  4. Kevin Krenitsky2009–2010

Chief financial officer

  1. Barry W. Weiner2007–2019
  2. David Bench2020–2022

Chief operating officer

  1. Andrew P. Whiteley2011–2014
  2. Kara Cannon2022–2023
2010201520202025
Board members and other officers (31)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDieter Schapfel, M.D. named Jun 5, 202358
  • Executive OfficerMatthew Kupferberg named Jun 5, 202358
  • Executive OfficerPatricia Eckert named Jun 5, 202358
  • DirectorElazar L. Rabbani, Ph.D. named Jun 5, 202358

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Enzo Life Sciences (ELS) AG, in Lausen, Switzerland, a wholly-owned5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 20, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights59
  2. Aug 19, 20258-K Shareholder vote60
  3. Jun 24, 20258-K Entered a material agreement; Regulation FD disclosure61
  4. Apr 22, 20258-K Other events62
  5. Apr 21, 20258-K Listing notice or transfer63
  6. Mar 31, 20258-K Listing notice or transfer; Regulation FD disclosure64
  7. Mar 18, 20258-K Results of operations65
  8. Jan 16, 20258-K Shareholder vote66
  9. Jan 15, 20258-K Other events67
  10. Jan 14, 20258-K Listing notice or transfer; Regulation FD disclosure68
  11. Nov 25, 20248-K Executive or director change69
  12. Oct 30, 20248-K Results of operations70
  13. Feb 27, 2024New chief executive Kara Cannon becomes CEO20
  14. Nov 10, 2021New chief executive Hamid Erfanian becomes CEO21
  15. Jan 24, 2007New chief executive Elazar Rabbani becomes CEO22

Calendar

When it reported results

  1. Mar 18, 2025Reported quarterly or annual results65
  2. Oct 30, 2024Reported quarterly or annual results70
  3. Mar 13, 2024Reported quarterly or annual results71

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

218 filings to the SEC since October 2021: 8 annual reports, 12 quarterly reports, 47 major events, 57 insider forms, 25 large holders, 1 private raises, 68 other. The latest 20:

  1. Nov 14, 2025SCHEDULE 13G/A EDGAR
  2. Aug 29, 2025EFFECT EDGAR
  3. Aug 29, 2025EFFECT EDGAR
  4. Aug 22, 2025SCHEDULE 13D/A EDGAR
  5. Aug 20, 202515-12G EDGAR
  6. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  7. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  8. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  9. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  10. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  11. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  12. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  13. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  14. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  15. Aug 20, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO TO FORM S-8 EDGAR
  16. Aug 20, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  17. Aug 20, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  18. Aug 20, 20254 EDGAR
  19. Aug 20, 20254 EDGAR
  20. Aug 20, 20254 EDGAR

The 218 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 13 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 13, 2023Wolf James G.Buy10,000$1.29$12.9KForm 4
Feb 10, 2023Wolf James G.Buy5,000$1.29$6.5KForm 4
Jan 27, 2023Wolf James G.Buy11,800$1.40$16.5KForm 4
Nov 23, 2022Erfanian HamidChief Executive OfficerBuy100,000$1.97$197.0KForm 4
Nov 1, 2022Wolf James G.Buy8,500$2.14$18.2KForm 4
Oct 31, 2022Wolf James G.Buy14,500$2.15$31.2KForm 4
Jul 15, 2022Cannon KaraChief Executive OfficerBuy2,500$2.42$6.0KForm 4
Jul 12, 2022Radoff Bradley LouisDirectorBuy12,500$2.27$28.4KForm 4
Jul 5, 2022Radoff Bradley LouisDirectorBuy120,000$2.20$264.0KForm 4
Jun 16, 2022Radoff Bradley LouisDirectorBuy75,000$2.20$165.0KForm 4
Jun 15, 2022Erfanian HamidChief Executive OfficerBuy4,600$2.19$10.1KForm 4
Jun 15, 2022Radoff Bradley LouisDirectorBuy50,000$2.21$110.5KForm 4
Jun 14, 2022Bench DavidChief Financial OfficerBuy3,500$2.15$7.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Kara Cannon56$376.4K$999.4K82
2024Hamid Erfanian$192.0K$820.4K82
2024Patricia Eckert47$264.2K$490.0K82
2023Former ChiefExecutive Officer$615.9K$2.7M82
2023Chief Executive Officer$298.5K$1.4M82
2023Chief Financial Officer$204.5K$503.6K82

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 19, 2023Raised $7 million in a private offering of securities Form D: 3 investors so far Form D

SEC filer profile

How ENZO BIOCHEM INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARENZO BIOCHEM INC1
  • CIK0000316253
  • Employer ID (EIN)13-28662026
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
  • Incorporated inNew York6
  • Fiscal year endsJuly 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address60 Executive Blvd, Farmingdale, NY 117351
  • Mailing addressEnzo Biochem Inc, 60 Executive Blvd, Farmingdale, NY 117351
  • Phone51675555001
  • Shares outstanding52,402,804 as of Jun 10, 202514
  • Public float$57.5M as of Jan 31, 20246
  • AuditorEisnerAmper LLP, West Palm Beach, Florida PCAOB ID 274; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceMar 20, 19951
  • Filings1,149 in all: 4 (304), 8-K (223), 10-Q (92), SC 13G/A (67), SC 13D/A (42), DEFA14A (39), DFAN14A (32), UPLOAD (30)1
    All 56 form types

    10-K (27), 3 (26), DEF 14A (26), 11-K (22), CORRESP (22), SC 13G (20), 4/A (15), 10-K/A (12), S-8 POS (12), EFFECT (9), PREC14A (9), S-3 (9), S-8 (9), 10-Q/A (7), S-3/A (7), 5 (6), 8-K/A (6), ARS (6), DEFC14A (6), SC 13D (6), 424B5 (5), DEFR14A (4), NT 10-Q (4), NT 11-K (4), PRER14A (4), PRRN14A (4), 10-K405 (3), 424B3 (3), SCHEDULE 13D/A (3), 3/A (2), DEFM14A (2), POS AM (2), PREM14A (2), RW (2), 15-12G (1), 25 (1), 8-A12B (1), CT ORDER (1), D (1), DFRN14A (1), FWP (1), NO ACT (1), NT 10-K (1), PRE 14A (1), S-3ASR (1), SCHEDULE 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Oct 29, 2024
    Quarterly report (10-Q) Jun 16, 2025
    Proxy statement (DEF 14A) Nov 27, 2024
    Latest 8-K (8-K) Aug 20, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $.01 par valueENZThe New York Stock Exchange

From the cover page of the 10-K filed Oct 29, 2024 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks ENZO BIOCHEM INC names in Item 1A of its 10-K filed Oct 29, 2024: 29 risks under these headings, as written.6

  • Business Risks
  • Our operating results may vary from period to period.
  • A significant proportion of our Products revenues are from academic centers, funded by government grants in our major markets globally.
  • A significant proportion of our Products revenues are from customers in pharmaceutical and biotech companies.
  • Our future success will depend in part upon our ability to enhance existing products, develop and introduce new products and realize commercial acceptance of those products, in a rapidly changing technological environment.
  • Our inability to carry out certain of our marketing and sales plans may make it difficult for us to grow or maintain our business.
  • We face significant competition, which could cause us to decrease the prices for our products or render our products uneconomical or obsolete, any of which could reduce our revenues and limit our growth.
  • We depend on distributors and contract manufacturers and suppliers for materials, which could impair our ability to manufacture or distribute our products.
  • We use hazardous materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be costly and time-consuming.
  • Risks relating to our Intellectual Property and Regulatory Approval
  • We are currently subject to, and may in the future become subject to additional, U.S. state and federal, and non-U.S. laws and regulations, industry guidelines, and contracts, imposing obligations on how we collect, store, use and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.
  • Protecting our proprietary rights is difficult and costly. If we fail to adequately protect or enforce our proprietary rights, we could lose potential revenue from licensing and royalties.
The other 19 risks
  • Lawsuits, including claimed patent infringements, in the biotechnology industry are not uncommon. If we become involved in any significant litigation, we would suffer as a result of the diversion of our management’s attention, the expense of litigation and any judgments against us.
  • We market certain of our products as Research Use Only, or RUO, in the United States. Our RUO products support the research and development activities conducted by academic/research institutions and biopharmaceutical companies of potential diagnostic and therapeutic products and services for which they may later pursue investigation and clearance, authorization or approval from regulatory authorities, such as the FDA.
  • If we are unable to meet regulatory quality and manufacturing requirements and standards applicable to the products we manufacture, our business, financial condition and operating results could be harmed.
  • Financial Risks
  • We have experienced significant losses in our continuing operations in fiscal years ended July 31, 2024 and 2023, and our losses have resulted in the use of cash in operations. If such losses and cash uses continue, the value of your investment could decline significantly.
  • Other risks relating to our business
  • Our failure to establish and maintain effective internal controls over financial reporting and information technology access could result in material misstatements in our consolidated financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
  • Material weaknesses in our internal control over financial reporting could materially adversely affect our ability to timely and accurately report our results of operations and financial condition. The accuracy of Enzo’s financial reporting depends on the effectiveness of its internal controls over financial reporting.
  • Cyber security risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet applications and related tools and functions could result in damage to the Company’s reputation and/or subject the Company to costs, fines, or lawsuits.
  • We rely on network and information systems and other technology whose failure or misuse could cause, and has caused, a disruption of services or loss or improper disclosure of personal data, business information, including intellectual property, or other confidential information, resulting in increased costs, loss of revenue or other harm to our business.
  • If we fail to attract and retain key personnel, including our senior management, our business could be adversely affected.
  • The insurance we purchase to cover our potential business risk may be inadequate.
  • We are, and may become subject to, legal proceedings, arbitration proceedings, investigations, and other claims or disputes, which are costly to defend and, if determined adversely to us, could require us to pay fines or damages, undertake remedial measures, or prevent us from taking certain actions, any of which could adversely affect our business.
  • Risks relating to our international operations
  • Foreign currency exchange rate fluctuations may adversely affect our business.
  • We are subject to economic, political and other risks associated with our significant international business, which could adversely affect our financial results.
  • With our commercialization activities outside of the United States, we are subject to the risk of inadvertently conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act and similar laws. If that occurs, we may be subject to civil or criminal penalties which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • International political, compliance and business factors, including the military conflict in Ukraine, the conflict in Gaza, and trade tensions between the U.S. and China, can negatively impact our operations and financial results.
  • Risks Relating to our Common Stock
  • Our stock price has been volatile, which could result in substantial losses for investors.
  • It may be difficult for a third party to acquire us, which could inhibit stockholders from realizing a premium on their stock price.
  • Future sales of shares of our common stock or the issuance of securities senior to our common stock could adversely affect the trading price of our common stock and our ability to raise funds in new equity offerings.
  • Our audit committee does not currently have three (3) independent members. If we fail to appoint an independent director that meets the New York Stock Exchange listing requirements for audit committees, the New York Stock Exchange could delist our common stock.

Legal proceedings

Ransomware Attack

In April 2023, the Company experienced a ransomware attack (the “ransomware attack”) that impacted certain critical information technology systems, principally of the discontinued operation. The Company later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company’s information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company determined that some employees’ information may have been involved. The Company provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law.

As a result of the ransomware attack, Enzo was subject to regulatory inquiry from the New York Attorney General, a joint inquiry from the Connecticut and New Jersey Attorneys General and an inquiry from the Utah Attorney General. All inquiries asked questions about the ransomware attack, as well as the corrective actions taken in response. The Company responded to all such inquiries, and there have been no further inquiries from the Utah Attorney General. The matters with the New York, Connecticut and New Jersey Attorneys General are now closed, as they were resolved by agreements with each of the three states signed on August 8, 2024 for New York, August 12, 2024 for Connecticut, and August 13, 2024 for New Jersey. A provision was recorded in the consolidated financial statements as of July 31, 2024 based on the settlement terms of the agreements.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
    SEC EDGAROther events
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
    SEC EDGAROther events
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82